Clinical syndromes and treatment location predict utility of carbapenem sparing therapies in ceftriaxone-non-susceptible Escherichia coli bloodstream infection.
Ouli XieKathryn CiseraLucy TaylorCarly HughesBenjamin RogersPublished in: Annals of clinical microbiology and antimicrobials (2020)
All tested agents could be used to replace a significant volume of carbapenem therapy. Establishing stability of these agents for use in OPAT is required for maximizing their use as carbapenem sparing agents while randomized clinical data is awaited for some of these agents in resistant E. coli bacteremia.
Keyphrases
- klebsiella pneumoniae
- gram negative
- escherichia coli
- acinetobacter baumannii
- multidrug resistant
- robot assisted
- open label
- randomized controlled trial
- drug resistant
- double blind
- pseudomonas aeruginosa
- stem cells
- electronic health record
- clinical trial
- big data
- mesenchymal stem cells
- placebo controlled
- phase iii
- minimally invasive